SR-9009 For Sale from $134.99/bottle: Compare Vendors & COAs

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SR-9009 Peptide For Sale

Buy SR-9009 peptide capsules. Compare live prices across 16+ vetted vendors with real cost per capsule, verified COAs and discount codes.

Buy SR-9009 peptide capsules starting at $134.99/bottle from 16+ vetted vendors. Compare capsule bottle options by cost per capsule, price per bottle, monthly cost, discount codes and independent COAs.

Where to Buy SR-9009 for Research

Finding a trustworthy SR-9009 supplier requires comparing more than just sticker price. Vendors differ in vial size, peptide concentration, COA frequency, lab selection, and shipping speed. WPA aggregates this data into a single, filterable comparison so researchers can quickly identify the best overall value for SR-9009 without visiting each vendor individually.

All SR-9009 vendors listed on WPA have been reviewed for COA availability. We prioritize suppliers who publish independently verified purity results from named third-party laboratories with recent test dates.

What This SR-9009 Comparison Page Includes

Live SR-9009 pricing — Current prices across all tracked vendors, normalized to price per milligram for a fair apples-to-apples comparison regardless of vial size.

COA verification data — Third-party purity test results for SR-9009, including the lab name, purity percentage, and test date so researchers can assess source quality.

Vendor discount codes — Exclusive WPA researcher discount codes that reduce the cost of SR-9009 from participating vendors.

Vial size and strength comparison — SR-9009 is sold in multiple concentrations and formats. WPA compares available strengths so lower vial prices do not conceal a higher true cost per milligram.

Stock availability — Real-time in-stock status for SR-9009 listings so researchers can plan sourcing without delays.

Shipping and handling context — Smaller vials may require more frequent purchases, each with shipping costs. WPA surfaces total research cost context beyond vial price alone.

SR-9009 Vendor Selection Methodology

WPA evaluates SR-9009 suppliers on four primary criteria: COA quality (purity ≥98%, named independent lab, recent test date), pricing transparency (per-milligram cost clearly disclosed), stock reliability (consistent availability tracked over time), and community trust (based on anonymized researcher click and purchase data collected through WPA tools).

Vendors that cannot provide verifiable third-party testing for SR-9009 are flagged accordingly. Researchers are encouraged to cross-reference COA data against the lab's published results before placing an order.

Frequently Asked Questions: SR-9009 Sourcing & Pricing

Why compare SR-9009 by price per milligram instead of vial price?

Vendors offer SR-9009 in different vial sizes and concentrations. A lower vial price may contain less total peptide, resulting in a higher cost per milligram. WPA normalizes all SR-9009 listings to $/mg so researchers see the true comparative value across all suppliers and strengths.

What should I check in a SR-9009 COA before purchasing?

A valid SR-9009 certificate of analysis should include the purity percentage (ideally 98% or higher), the name of an independent third-party laboratory, a recent test date (within the last 12 months), and the actual measured mass relative to the label claim. COAs without a named lab or with outdated test dates are red flags regardless of the purity figure listed.

How often does WPA update SR-9009 vendor data?

World Peptide Association monitors SR-9009 pricing and stock status continuously. COA verification status is updated whenever vendors publish new lab results. Researchers can check the "COA date" column on this page to see how recently each vendor's SR-9009 testing was performed.

Why do SR-9009 prices vary between vendors?

SR-9009 price variation reflects differences in vial size, synthesis source, testing frequency, and vendor business model. Suppliers investing in frequent independent COA testing and quality control typically have higher baseline costs. WPA's per-milligram normalization helps researchers identify whether a lower price represents genuine savings or simply a smaller vial.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching SR-9009 — share findings, ask questions, and learn from real experiences SR-9009 (Stenabolic) is a synthetic Rev-Erb agonist developed by Professor Thomas Burris at the Scripps Research Institute. Despite being almost universally marketed and sold alongside SARMs, SR-9009 is not a selective androgen receptor modulator and does not bind to or activate the androgen receptor in any capacity. Its mechanism is entirely distinct: it acts as an agonist of the Rev-Erb-alpha and Rev-Erb-beta nuclear receptors, which are key components of the molecular circadian clock and play critical roles in regulating lipid and glucose metabolism, inflammatory responses, and mitochondrial biogenesis. In preclinical studies conducted in mice, SR-9009 demonstrated notable effects on exercise capacity, metabolic rate, fat oxidation, and circadian rhythm regulation. Treated mice showed increased oxygen consumption, decreased fat mass, and enhanced endurance without changes in food intake. However, the most significant limitation of SR-9009 is its extremely poor oral bioavailability, estimated at approximately 2% in rodent models. This means that the vast majority of an orally administered dose is destroyed by first-pass hepatic metabolism before reaching systemic circulation. The impressive preclinical results were obtained via injection, raising serious questions about whether oral dosing in humans can achieve pharmacologically meaningful plasma concentrations. SR-9009 has never been tested in human clinical trials, is not approved for any medical use, and is classified as a prohibited substance by the World Anti-Doping Agency (WADA). It remains available through research chemical suppliers, where it is used in performance enhancement contexts primarily for its purported effects on fat loss, endurance, and energy levels. SR-9009 functions as a synthetic agonist of the Rev-Erb-alpha (NR1D1) and Rev-Erb-beta (NR1D2) nuclear receptors. Rev-Erb proteins are constitutive transcriptional repressors that form a critical negative feedback loop within the mammalian circadian clock. They repress the transcription of BMAL1 and CLOCK, core clock genes that drive circadian oscillation of gene expression throughout the body. By activating Rev-Erb receptors, SR-9009 modulates circadian gene expression and thereby influences a broad array of downstream metabolic processes. In skeletal muscle, Rev-Erb activation by SR-9009 increases mitochondrial content and oxidative capacity. The compound upregulates genes involved in mitochondrial biogenesis, fatty acid oxidation, and glucose utilization. Studies in mice demonstrated that SR-9009 treatment increased the number of mitochondria in skeletal muscle, enhanced oxygen consumption, and improved exercise endurance. In the liver, Rev-Erb activation suppresses genes involved in lipogenesis (de novo fat synthesis) and gluconeogenesis, resulting in reduced hepatic fat accumulation and improved glucose homeostasis. In adipose tissue, SR-9009 reduces fat storage by downregulating genes involved in triglyceride synthesis. The net metabolic effect is an increase in energy expenditure and a shift toward a leaner metabolic phenotype. Critically, because SR-9009 acts through the Rev-Erb pathway and not the androgen receptor, it does not cause testosterone suppression, does not affect the hypothalamic-pituitary-gonadal axis, and does not require post-cycle therapy. The compound is entirely non-hormonal in its mechanism.

Source: peptide-db.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Quick Dosing Reference · research convention, not a validated dose

2 caps/day (split 2x) 20mg/day Starting dose (10mg AM + 10mg PM) 3 caps/day (split 3x) 30mg/day Standard research dose (10mg AM + 10mg Noon + 10mg PM)

Source: pathtopeptides.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →